These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12162678)

  • 21. [Immunohistochemical study of the prostate-specific antigen in prostatic cancer].
    Karseladze AI; Rytin IIe; Budunova IV
    Arkh Patol; 2004; 66(2):3-7. PubMed ID: 15154373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
    Alanen KA; Kuopio T; Koskinen PJ; Nevalainen TJ
    Pathol Res Pract; 1996 Mar; 192(3):233-7. PubMed ID: 8739470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases.
    Mai KT; Roustan Delatour NL; Assiri A; Al-Maghrabi H
    Diagn Cytopathol; 2007 Feb; 35(2):91-5. PubMed ID: 17230567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
    Mhawech P; Uchida T; Pelte MF
    Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
    Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
    Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Kunju LP; Mehra R; Snyder M; Shah RB
    Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
    Varma M; Jasani B
    Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining.
    Varma M; Berney DM; Jasani B; Rhodes A
    J Clin Pathol; 2004 Jul; 57(7):687-90. PubMed ID: 15220358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of sensitivity using hybrid stimulus for the diagnosis of prostate cancer based on polydiacetylene (PDA) supramolecules.
    Kwon IK; Kim JP; Sim SJ
    Biosens Bioelectron; 2010 Dec; 26(4):1548-53. PubMed ID: 20732801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S].
    Xiao Q; Yin H; Lu Z; Meng K; Zhou X
    Zhonghua Nan Ke Xue; 2004 May; 10(5):362-5. PubMed ID: 15190830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and measurement of prostate-specific antigen using monoclonal antibodies.
    Bélanger A; Rong PM; Liu S; Lavoie L; Labrie F
    Clin Invest Med; 1993 Dec; 16(6):409-14. PubMed ID: 7516829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.
    Kunju LP; Rubin MA; Chinnaiyan AM; Shah RB
    Am J Clin Pathol; 2003 Nov; 120(5):737-45. PubMed ID: 14608901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
    Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
    Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.